Detalles de la búsqueda
1.
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
J Med Chem
; 64(1): 644-661, 2021 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33356246
2.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
; 60(7): 3002-3019, 2017 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28287730
3.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24819116
4.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24432909
Resultados
1 -
4
de 4
1
Próxima >
>>